Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
TROP2 is an actionable target in the treatment of triple-negative breast cancer (TNBC) owing to its high expression on tumor cells and low expression on healthy tissue. TROP2-targeting antibody-drug conjugates (ADCs) deliver potent cytotoxic chemotherapy to cancer cells. In this activity, 3 experts discuss their strategies for incorporating ADCs into the treatment of TNBC and predict future applications of ADCs for TNBC based on the latest trial data.
Target Audience
This activity is directed toward medical oncologists, advanced practice providers, nurses, pharmacists, and other health care practitioners who manage breast cancer.
Learning Objectives
- Develop evidence-based strategies for integrating ADCs in the management of patients with metastatic TNBC
- Apply effective methods to mitigate adverse effects associated with ADCs in patients with metastatic TNBC